SI
SI
discoversearch


 Biotech / Medical: Provectus Pharmaceuticals Inc.  
Posts: 12797 | Member SubjectMarks: 106 | No Bans

Share This Board Moderated By: Jack Russell -- (Moderated) -- Started: 4/16/2006 9:15:35 PM  Revision History

PVCT 2.110.0%Apr 16 8:10 PM EDTNews



This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:

PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read detailed Research Reports

------------------------------------------------------------------------------------------------------------------------------------------------------

Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com  a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.

The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com  The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.

-------------------------------------------------------------------------------------------------------------------------------------------------------



Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com 

August 19, 2008
PV-10 for Melanoma Story Airs on ABC's 7:30 Report in Australia
The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10.
pvct.com 




PVCT on YouTube...
youtube.com 

theze.cn 

--------------------------------------------------------------

PVCT insiders transactions:
secform4.com 

--------------------------------------------------------------


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302


Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com


Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com


Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031



--------------------------------------------------------------
Company Website


pvct.com 

==============================================================
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsDate
12797I would agree completely Rutgers... Jack Russell-04/16/2014 09:25 AM
12796*If* the upcoming news over the next five weeks through end of year is overall pRutgers104/16/2014 09:21 AM
12795Yes it does and considering I am up over 200% on my investment it speaks very weJack Russell-04/16/2014 09:15 AM
12794He's an investor that lives in Knoxville and claims to have a relationship wCharlestonBuckeye-04/16/2014 07:20 AM
12793s/p speaks for itself! CharlestonBuckeye-04/16/2014 07:13 AM
12792No problem - not taken that way. Mark Buczynski-04/16/2014 05:28 AM
12791I agree completely... Sorry did not mean to come off as I was correcting you jusJack Russell-04/15/2014 10:58 PM
12790Not to sound like 2 old biddies here.. he said she said but... Maybe he was reMark Buczynski-04/15/2014 10:11 PM
12789Mark That is not Vorlons Blog/Site. It is Doms site (Dominic Rodriguez) AKA PVCTJack Russell-04/15/2014 08:30 PM
12788This is a cut & paste from his blog of yesterday... This what he referred tMark Buczynski-04/15/2014 07:05 PM
12787As far as I know Mark he is a poster/shareholder on some of the other threads whJack Russell-04/15/2014 06:54 PM
12786Anyone care to share who vorlan1966 is? Tks. Mark Buczynski-04/15/2014 05:42 PM
12785You make such convincing arguments... LOL Not Jack Russell-04/15/2014 05:30 PM
12784then don't read them and keep throwing good bad money after bad. CharlestonBuckeye-04/15/2014 03:37 PM
12783Gosh. You started posting the day after the AF-inspired short assault and have pincus-04/15/2014 12:51 PM
12782This is done! CharlestonBuckeye-04/15/2014 12:18 PM
12781Anyone here have access to daily (or thereof) short interest on the stock? I doMark Buczynski-04/15/2014 10:26 AM
12780Most I ever paid for these shares, but purchased several more today...speaking oRutgers104/14/2014 05:18 PM
12779Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital Howard Williams-04/14/2014 07:26 AM
12778DRs. Weber and Ross had a debate in which the question of using intralesional aroadcoach-04/13/2014 06:51 PM
12777Welcome back, I haven't left - still lurking - but I was lucky enough to makNOREG-04/10/2014 01:13 PM
12776Great Post Mark and I wholeheartedly agree... Things are coming together fast noJack Russell-04/10/2014 11:45 AM
12775SG - first sorry to hear about your Dad. Such a shame, especially when we know Mark Buczynski-04/10/2014 11:07 AM
12774Despite selling virtually all my PVCT at nasty losses and abandoning this board,SG-04/10/2014 10:34 AM
12773Great posts worth the read... Jack Russell-04/07/2014 06:46 PM
12772He has a new one just up. trustintelligence.com  Mimbari-04/07/2014 04:50 PM
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.